IGF-I improved bone mineral density and body composition of weaver mutant mice

Growth Hormone and IGF Research

Volumn 18, Issue 6, 2008, Pages 517-525

  Yao, Weiguo ^a   Zhong, Jin ^a   Yu, Jun ^a   Warner, Therry ^a   Bozic, Tomica ^a,b   Ye, Ping ^c   Joseph D'Ercole, A ^c   Hock, Janet M ^a   Lee, Wei Hua ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Clinical Hospital   (Bosnia and Herzegovina)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

BMD; Body composition; IGF I; Weaver mice

Indexed keywords

SOMATOMEDIN C;

ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY FAT; BODY WEIGHT; BONE DENSITY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROWTH HORMONE DEFICIENCY; LEAN BODY WEIGHT; MALE; MOUSE; MUTANT; NONHUMAN; POSTNATAL GROWTH; PREPUBERTY; PRIORITY JOURNAL; PROTEIN FUNCTION; PUBERTY; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BODY COMPOSITION; BODY WEIGHT; BONE DENSITY; CEREBELLAR ATAXIA; FEMALE; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, NEUROLOGIC MUTANTS;

EID: 53449102847     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.04.006     Document Type: Article

References (60)

1. Bachrach L.K., et al. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J. Bone Miner. Res. 13 (1998) 415-421
2. Bhasin S., et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J. Clin. Endocrinol. Metab. 82 (1997) 407-413
3. Bikle D., et al. The skeletal structure of insulin-like growth factor I-deficient mice. J. Bone Miner. Res. 16 (2001) 2320-2329
4. Boguszewski C.L., et al. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur. J. Endocrinol. 152 (2005) 67-75
5. Boot A.M., et al. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 82 (1997) 2423-2428
6. Bouxsein M.L., et al. Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J. Bone Miner. Res. 17 (2002) 570-579
7. Bowsher R.R., et al. Measurement of insulin-like growth factor-II in physiological fluids and tissues. I. An improved extraction procedure and radioimmunoassay for human and rat fluids. Endocrinology 128 (1991) 805-814
8. Caviness Jr. V.S., and Rakic P. Mechanisms of cortical development: a view from mutations in mice. Ann. Rev. Neurosci. 1 (1978) 297-326
9. Compston J.E. Sex steroids and bone. Physiol. Rev. 81 (2001) 419-447
10. Dai Z., et al. Creation of an autocrine model of insulin-like growth factor-I action in transfected FRTL-5 cells. Endocrinology 130 (1992) 3175-3183
11. Donahue L.R., and Beamer W.G. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J. Endocrinol. 136 (1993) 91-104
12. H.K.B.J. Genant, P. Steiger et al., 1987. Quantitative computed tomography in the assessment of osteoporosis. Osteoporosis Update 1987. Berkeley, California, University of California Press, pp. 49-71.
13. Ghigo E., et al. Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am. J. Physiol. 276 (1999) E1009-E1013
14. Goldowitz D. The weaver granuloprival phenotype is due to intrinsic action of the mutant locus in granule cells: evidence from homozygous weaver chimeras. Neuron 2 (1989) 1565-1575
15. Gori F., et al. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocrinology 140 (1999) 5579-5586
16. Grinspoon S., et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J. Clin. Endocrinol. Metab. 81 (1996) 4051-4058
17. He J., et al. Postnatal growth and bone mass in mice with IGF-I haploin sufficiency. Bone 38 (2006) 826-835
18. Johansson A.G., et al. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. J. Int. Med. 232 (1992) 447-452
19. Jorgensen J.O., et al. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. Eur. J. Endocrinol. 130 (1994) 224-228
20. Katznelson L., et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81 (1996) 4358-4365
21. Laron Z., and Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm. Res. 40 (1993) 16-22
22. Lesage F., et al. Cloning provides evidence for a family of inward rectifier and G-protein coupled K+ channels in the brain. FEBS Lett. 353 (1994) 37-42
23. Leung K.C., et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc. Natl. Acad. Sci. USA 100 (2003) 1016-1021
24. Leung K.C., et al. Estrogen regulation of growth hormone action. Endocrinol. Rev. 25 (2004) 693-721
25. Libanati C., et al. Studies on the potential mediators of skeletal changes occurring during puberty in girls. J. Clin. Endocrinol. Metab. 84 (1999) 2807-2814
26. Maor G., et al. Testosterone stimulates insulin-like growth factor-I and insulin-like growth factor-I-receptor gene expression in the mandibular condyle - a model of endochondral ossification. Endocrinology 140 (1999) 1901-1910
27. Mauras N., et al. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J. Clin. Endocrinol. Metab. 85 (2000) 3036-3042
28. Mauras N., et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism. J. Clin. Endocrinol. Metab. 85 (2000) 1686-1694
29. Mohan S., and Baylink D.J. Impaired skeletal growth in mice with haploin sufficiency of IGF-I: genetic evidence that differences in IGF-I expression could contribute to peak bone mineral density differences. J. Endocrinol. 185 (2005) 415-420
30. Mohan S., et al. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology 144 (2003) 929-936
31. Moller N., et al. Dose-response studies on the metabolic effects of a growth hormone pulse in humans. Metabolism 41 (1992) 172-175
32. Moreira-Andres M.N., et al. Correlations between bone mineral density, insulin-like growth factor I and auxological variables. Eur. J. Endocrinol. 132 (1995) 573-579
33. Patil N., et al. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Natl. Genet. 11 (1995) 126-129
34. Ranke M.B., et al. Experience with insulin-like growth factor I (IGF-I) treatment of growth hormone insensitivity syndrome (GHIS). J. Pediatr. Endocrinol. Metab. 12 Suppl. 1 (1999) 259-266
35. Richman C., et al. Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice. J. Bone Miner. Res. 16 (2001) 386-397
36. Rosen C.J., et al. Allelic differences in a quantitative trait locus affecting insulin-like growth factor-I impact skeletal acquisition and body composition. Pediatr. Nephrol. 20 (2005) 255-260
37. Rosen C.J., et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program. Bone 35 (2004) 1046-1058
38. Rosen C.J., et al. Circulating and skeletal insulin-like growth factor-I (IGF-I) concentrations in two inbred strains of mice with different bone mineral densities. Bone 21 (1997) 217-223
39. Saban J., et al. Erythroid-specific expression of human growth hormone affects bone morphology in transgenic mice. Bone 18 (1996) 47-52
40. Schwartz N.B., et al. Hypothalamic-pituitary-gonadal axis in the mutant weaver mouse. Neuroendocrinology 68 (1998) 374-385
41. Sjogren K., et al. Effects of liver-derived insulin-like growth factor I on bone metabolism in mice. J. Bone Miner. Res. 17 (2002) 1977-1987
42. Slesinger P.A., et al. Functional effects of the mouse weaver mutation on G protein-gated inwardly rectifying K+ channels. Neuron 16 (1996) 321-331
43. Smeyne R.J., and Goldowitz D. Development and death of external granular layer cells in the weaver mouse cerebellum: a quantitative study. J. Neurosci. 9 (1989) 1608-1620
44. Snyder D.K., et al. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J. Clin. Endocrinol. Metab. 67 (1988) 54-61
45. Snyder P.J., et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 (1999) 1966-1972
46. Snyder P.J., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84 (1999) 2647-2653
47. Svensson J., et al. Effects of GH and insulin-like growth factor-I on body composition. J. Endocrinol. Invest. 26 (2003) 823-831
48. Thompson J.L., et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J. Clin. Endocrinol. Metab. 80 (1995) 1845-1852
49. Vahl N., et al. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J. Clin. Endocrinol. Metab. 82 (1997) 3612-3618
50. Veldhuis J.D., et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocrinol. Rev. 26 (2005) 114-146
51. Woods K.A., et al. Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr. Suppl. 423 (1997) 39-45
52. Woods K.A., et al. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J. Clin. Endocrinol. Metab. 85 (2000) 1407-1411
53. Yakar S., et al. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110 (2002) 771-781
54. Yao W., et al. Role of the GH/IGF-I axis in the growth retardation of weaver mice. Endocrine 32 (2007) 227-234
55. Yao W., et al. IGF-I and postnatal growth of weaver mutant mice. Endocrine 26 (2005) 117-125
56. Ye P., et al. In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors. Brain Res. Dev. Brain Res. 95 (1996) 44-54
57. Zhang M., et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277 (2002) 44005-44012
58. Zhao G., et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141 (2000) 2674-2682
59. Zhong J., et al. Inhibition of insulin-like growth factor I activity contributes to the premature apoptosis of cerebellar granule neuron in weaver mutant mice: in vitro analysis. J. Neurosci. Res. 70 (2002) 36-45
60. Zhong J., et al. Insulin-like growth factor-I protects granule neurons from apoptosis and improves ataxia in weaver mice. J. Neurosci. Res. 80 (2005) 481-490